Typhoid Fever - Pipeline Insight, 2024

This “Typhoid Fever - Pipeline Insight, 2024” report provides comprehensive insights about 3+ companies and 4+ pipeline drugs in Typhoid Fever pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Typhoid Fever: Understanding

Typhoid Fever: Overview

Typhoid fever, caused by the bacterium Salmonella Typhi, is a life-threatening infection primarily spread through contaminated food or water. This disease, characterized by symptoms like prolonged high fever, fatigue, headache, abdominal pain, and diarrhea, poses a significant public health challenge globally. With an estimated 9 million cases and 110,000 deaths annually, typhoid fever remains a concern, especially in regions with poor sanitation and limited access to safe water. The emergence of antibiotic resistance further complicates treatment, necessitating more complex and costly therapeutic approaches in heavily affected areas. Vaccination, improved sanitation, and hygiene practices play crucial roles in preventing the spread of typhoid fever. As urbanization and climate change potentially increase the disease burden, understanding the epidemiology, risk factors, and treatment options for typhoid fever is essential for effective public health interventions and disease control strategies.

Typhoid fever presents with a range of signs and symptoms that typically develop 1 to 2 weeks after infection with the Salmonella Typhi bacteria. The hallmark symptom is a persistent high fever that gradually increases each day, often reaching temperatures as high as 103-104°F (39-40°C). This sustained fever distinguishes typhoid fever from other febrile illnesses. Alongside fever, individuals may experience weakness, stomach pain, headache, constipation or diarrhea, cough, and loss of appetite. In some cases, a rash with flat, rose-colored spots, known as "rose spots," may appear. Prompt medical attention is crucial if these symptoms manifest, as untreated typhoid fever can worsen over weeks, leading to severe complications and posing a risk of life-threatening outcomes. Treatment with antibiotics is essential to manage the infection effectively and prevent potential long-term health issues.

The treatment and management of typhoid fever involve a multifaceted approach aimed at addressing the infection and its complications effectively. Supportive measures play a crucial role, including oral or intravenous hydration, tepid baths, appropriate nutrition, and blood transfusions if necessary. Over 90% of patients can be managed at home with oral antibiotics under the supervision of a reliable caretaker and close medical follow-up to monitor for complications or treatment response. Antibiotic therapy is essential for eradicating the Salmonella Typhi bacteria causing typhoid fever. Various antibiotics, such as fluoroquinolones, cephalosporins, macrolides, and carbapenems, are commonly prescribed based on the strain's susceptibility. In severe cases, the use of steroids like dexamethasone may be considered. Surgical intervention is reserved for complications like intestinal perforation. Good nursing care, fluid and electrolyte management, and a soft digestible diet are integral parts of typhoid fever management. Vaccination, hand hygiene, and safe food handling practices are crucial for prevention and control, emphasizing the importance of a comprehensive approach to combat this potentially life-threatening infection.

"Typhoid Fever - Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Typhoid Fever pipeline landscape is provided which includes the disease overview and Typhoid Fever treatment guidelines. The assessment part of the report embraces, in depth Typhoid Fever commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Typhoid Fever collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Typhoid Fever R&D. The therapies under development are focused on novel approaches to treat/improve Typhoid Fever.

Typhoid Fever Emerging Drugs Chapters

This segment of the Typhoid Fever report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Typhoid Fever Emerging Drugs

GSK-4077164A: GlaxoSmithKline

GSK-4077164A is developed by GlaxoSmithKline to treat the patients suffering from typhoid fever. The vaccine act as an immunostimulant and is administered via intramuscular route. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with Typhoid Fever.

Typhoid Fever: Therapeutic Assessment

This segment of the report provides insights about the different Typhoid Fever drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Typhoid Fever

There are approx. 3+ key companies which are developing the therapies for Typhoid Fever. The companies which have their Typhoid Fever drug candidates in the most advanced stage, i.e. Phase II include, GlaxoSmithKline.

Phases

DelveInsight’s report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Typhoid Fever pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Typhoid Fever: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Typhoid Fever therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Typhoid Fever drugs.

Typhoid Fever Report Insights

• Typhoid Fever Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Typhoid Fever Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Typhoid Fever drugs?
• How many Typhoid Fever drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Typhoid Fever?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Typhoid Fever therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Typhoid Fever and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• GlaxoSmithKline
• PT Bio Farma
• Matrivax

Key Products

• GSK-4077164A
• Vi-DT
• Typhax

This product will be delivered within 2 business days.